After-hours movers: HP Inc., Dell Technologies, Workday and more

After-Hours Stock Movers:

HP Inc. (NYSE:HPQ ) fell 7.5% after it issued lackluster guidance. For fiscal 2025, HP estimates non-GAAP diluted net EPS to be in the range of $3.45 to $3.75, about in-line with consensus.

Dell Technologies (NYSE:DELL ) fell 6% despite beating estimates for third quarter EPS and revenue. Revenue was $24.4 billion, up 10% year over year. Diluted earnings per share was $1.58, and non-GAAP diluted earnings per share was $2.15, up 16% and 14% year over year, respectively.

Autodesk(NASDAQ:ADSK ) fell 7.7% despite beating estimates and raising guidance. Third quarter total revenue increased 11% to $1.57 billion.

Workday (NASDAQ:WDAY ) fell 8% despite beating third quarter results, after it issued disappointing guidance. It sees Q4 subscription revenue of $2.025 billion, slightly below consensus of $2.04 billion.

CrowdStrike(NASDAQ:CRWD ) fell 2.1% after beating third quarter results. Total revenue was $1,010.2 million, a 29% increase, compared to $786.0 million in the third quarter of fiscal 2024. Subscription revenue was $962.7 million, a 31% increase, compared to $733.5 million in the third quarter of fiscal 2024.

Urban Outfitters (NASDAQ:URBN ) rose 5% after it published strong quarterly EPS and revenue. Total Company net sales for the three months ended October 31, 2024, increased 6.3% to a record $1.36 billion.

Nordstrom (NYSE:JWN ) fell 1% despite beating estimates for its third quarter. Total Company net sales increased 4.6 percent and comparable sales increased 4.0 percent compared with the same period in fiscal 2023.

Ambarella (NASDAQ:AMBA ) surged 25% after results beat the average analyst estimate and it issued strong guidance for the final quarter of the year. Revenue for the third quarter of fiscal 2025 was $82.7 million, up 63% from $50.6 million in the same period in fiscal 2024.

PTC Therapeutics (NASDAQ:PTCT ) fell 13% after its Phase 2 placebo-controlled CardinALS study did not meet its primary endpoint of slowing disease progression on the composite ALSFRS-R and mortality analysis.

Source: Investing.com